AMANDA SHULSKI: Open Payments
NPI 1700513025 · PHILADELPHIA, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,846 in 167 payments from 19 companies in 2025. Trend: 2023 $92 · 2024 $490 · 2025 $3,846
Food & beverage: $3,846
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 33 | $695 |
| Madrigal Pharmaceuticals | 23 | $578 |
| Janssen Biotech, Inc. | 25 | $541 |
| Ardelyx, Inc. | 19 | $495 |
| Janssen Scientific Affairs, LLC | 3 | $369 |
| QOL Medical, LLC | 15 | $305 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 15 | $239 |
| Aimmune Therapeutics, Inc. | 11 | $169 |
| Lilly USA, LLC | 4 | $79 |
| Braintree Laboratories, Inc. | 3 | $72 |
Products named: TREMFYA, REZDIFFRA, IBSRELA, Sucraid, RINVOQ, XIFAXAN, ZENPEP, CREON.
Industry payments across PA — which companies pay providers there.
